Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Hydroxychloroquine (HCQ)|DRUG: Gedatolisib
Sponsor: Abramson Cancer Center at Penn Medicine
Collaborators: Translational Breast Cancer Research Consortium|Pfizer|Hoosier Cancer Research Network|Breast Cancer Research Foundation